The Filing Desk

Lexicon Pharmaceuticals vs Nektar Therapeutics

Lexicon Pharmaceuticals LXRX · Nektar Therapeutics NKTR · Pharmaceuticals

Nektar Therapeutics reported revenue of $55 million in fiscal 2025, about the same as Lexicon Pharmaceuticals' $50 million in fiscal 2025. Lexicon Pharmaceuticals' revenue grew 60.2% in its latest year, and Nektar Therapeutics' fell 43.9%. Lexicon Pharmaceuticals had an operating margin of -98.2%, against -253.7% at Nektar Therapeutics. Free cash flow was −$68 million at Lexicon Pharmaceuticals and −$209 million at Nektar Therapeutics.

Side by side

Lexicon PharmaceuticalsNektar Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$50M$55M
Revenue growth60.2%−43.9%
Revenue growth a year, last 5 years15.7%−18.4%
Gross margin99.5%100.0%
Operating margin−98.2%−253.7%
Net margin−101.1%−297.1%
Free cash flow−$68M−$209M
Free cash flow margin−136.2%−377.8%
Return on capital−105.0%—
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count13.4%23.1%
Last close$1.67$32.54
P/E at the last close——
Insider trades, last 12 monthsbought $2.7 million, sold $0sold $2.5 million
Piotroski F-score4 of 92 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Lexicon PharmaceuticalsNektar Therapeutics
Operating margin
Percent of revenue
Lexicon PharmaceuticalsNektar Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Lexicon PharmaceuticalsNektar Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Lexicon Pharmaceuticals and Nektar Therapeutics pages.